Evidence map›Paper›PMID 31744494›Full record

ArticleBMC cancer2019

Comparative transcriptome analysis of matched primary and distant metastatic ovarian carcinoma.

H Sallinen, S Janhonen, P Pölönen, H Niskanen, O H Liu, A Kivelä, J M Hartikainen, M Anttila, M Heinäniemi, S Ylä-Herttuala and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Molecular Management of High-Grade Serous Ovarian Carcinoma.International journal of molecular sciences · 2022
    Review
  7. Article
  8. Recent Multiomics Approaches in Endometrial Cancer.International journal of molecular sciences · 2022
    Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

H SallinenDepartment of Obstetrics and Gynecology, Kuopio University Hospital, Kuopio, Finland.
S JanhonenDepartment of Obstetrics and Gynecology, Kuopio University Hospital, Kuopio, Finland.
P PölönenInstitute of Biomedicine, School of Medicine, University of Eastern Finland, Kuopio, Finland.
H NiskanenA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland.
O H LiuA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland.
A KiveläA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland.
J M HartikainenInstitute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Kuopio, Finland.
M AnttilaDepartment of Obstetrics and Gynecology, Kuopio University Hospital, Kuopio, Finland.
M HeinäniemiInstitute of Biomedicine, School of Medicine, University of Eastern Finland, Kuopio, Finland.
S Ylä-HerttualaA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland.
M U KaikkonenA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland. minna.kaikkonen@uef.fi.
University of Eastern Finland · FIKuopio University Hospital · FI

Funding

Academy of Finland 287478
6 · The paper itself

Abstract

backgroundHigh grade serous ovarian carcinoma (HGSOC) is the most common subtype of epithelial ovarian cancers (EOC) with poor prognosis. In most cases EOC is widely disseminated at the time of diagnosis. Despite the optimal cytoreductive surgery and chemotherapy most patients develop chemoresistance, and the 5-year overall survival being only 25-35%.

methodsHere we analyzed the gene expression profiles of 10 primary HGSOC tumors and 10 related omental metastases using RNA sequencing and identified 100 differentially expressed genes.

resultsThe differentially expressed genes were associated with decreased embryogenesis and vasculogenesis and increased cellular proliferation and organismal death. Top upstream regulators responsible for this gene signature were NR5A1, GATA4, FOXL2, TP53 and BMP7. A subset of these genes were highly expressed in the ovarian cancer among the cancer transcriptomes of The Cancer Genome Atlas. Importantly, the metastatic gene signature was suggestive of poor survival in TCGA data based on gene enrichment analysis.

conclusionBy comparing the gene expression profiles of primary HGSOC tumors and their matched metastasis, we provide evidence that a signature of 100 genes is able to separate these two sample types and potentially predict patient survival. Our study identifies functional categories of genes and transcription factors that could play important roles in promoting metastases and serve as markers for cancer prognosis.

Indexed as

Gene Expression ProfilingTranscriptomeCarcinoma, Ovarian EpithelialCell Line, TumorComputational BiologyFemaleGene Expression Regulation, NeoplasticHigh-Throughput Nucleotide SequencingHumansKaplan-Meier EstimateNeoplasm MetastasisNeoplasm StagingOvarian NeoplasmsHGSOCMetastasisOvarian carcinomaRNA sequencingTranscriptome

Identifiers

PMID31744494
PMCPMC6862850
OpenAlexW2991393487

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.